EUS-guided Portal Pressure Gradient (PPG) Measurement: a Potential Alternative to the Traditional HVPG (EUS-PPG)

Fundacio Privada Mon Clinic Barcelona

Status

Not yet enrolling

Conditions

Portal Hypertension

Chronic Liver Disease (CLD)

Cirrhosis

Treatments

Diagnostic Test: Endoscopic Ultrasound-Guided Portal Pressure Gradient (EUS-PPG) Measurement

Diagnostic Test: Hepatic Venous Pressure Gradient (HVPG) Measurement

Study type

Interventional

Funder types

Other

Identifiers

NCT06863012

EUS-PPG

Details and patient eligibility

About

The goal of this investigator-initiated, single-arm, prospective study is to evaluate the accuracy, safety, and feasibility of endoscopic ultrasound-guided portal pressure gradient (EUS-PPG) measurement as a potential alternative to the traditional hepatic venous pressure gradient (HVPG) method in patients with portal hypertension due to chronic liver disease. The main questions it aims to answer are:

What is the correlation between EUS-PPG and HVPG measurements in patients with portal hypertension due to cirrhosis?
Can EUS-PPG serve as a reliable and less invasive alternative to HVPG for assessing portal pressure?
What are the safety outcomes associated with EUS-PPG compared to HVPG?

Researchers will compare EUS-PPG measurements with HVPG measurements within the same patients to assess whether EUS-PPG provides accurate and clinically comparable portal pressure readings while reducing procedural risks.

Participants will:

Be adults aged 18 to 85 with a history of liver disease and portal hypertension or suspected cirrhosis requiring HVPG measurement.
Undergo both EUS-PPG and HVPG measurements within a seven-day window to allow for direct comparison of results.
Receive standard clinical care for their condition, including routine diagnostic evaluations and portal hypertension management as needed.
Be monitored for safety outcomes, including adverse events such as bleeding, infection, perforation, and any other complications related to the procedure.
Provide relevant demographic and clinical data, including liver disease history, Child-Pugh and MELD scores, and portal hypertension-related complications such as varices or ascites.

Enrollment

20 estimated patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subjects must be 18 to 85 years of age inclusive, at the time of signing the informed consent form.
Subjects who have a history of liver disease and portal hypertension or suspected cirrhosis requiring HVPG measurement.
Subjects capable of giving signed informed consent.

Exclusion criteria

Pregnancy.
Significant bleeding risk (International Normalized Ratio (INR) > 1.5 OR platelet count < 50000).
Presence of active gastrointestinal bleeding at the time of screening
History of any blood thinner consumption (e.g. warfarin, heparin, novel roal anticoagulants) within the last 5 days.
Presence of massive ascites causing abdominal distension or requiring frequent therapeutic paracentesis.
Subjects having received previous Transjugular Intrahepatic Portosystemic Shunt (TIPS) or Surgical Portosystemic Shunt.
Hepatocellular carcinoma not meeting Milan Criteria.
Presence of portal vein thrombosis or another suspected component of presinusoidal portal hypertension.
Presence of extra-hepatic cancer, terminal disease, or severe comorbidities significantly limiting life expectancy or affecting study participation.
Stenosis or surgical anatomical alterations of the gastrointestinal tract that could preclude endoscopic access with the echoendoscope.